🚨 #ALLO SHORT-TERM --> LONG-TERM
Short-term (next 6–12 months): ALLO remains a speculative biotech — volatility may continue as markets react to trial data, regulatory #updates or cash-burn guidance.
Long-term (#2026 onward): If ALLO delivers on its promise — safe & effective allogeneic CAR-T therapies for cancer or autoimmune disease — the payoff could be significant. For risk-tolerant investors, this remains a “#HIGH risk, high reward” name.
